Life Sciences and Precision Medicine

Where blood meets imaging. A new standard for early detection.

Oatmeal Health partners with biotech and liquid biopsy companies to combine blood based molecular testing with our AI powered imaging analysis, giving life sciences companies, diagnostics innovators, and clinical researchers access to the patients and infrastructure they need to validate and deliver precision medicine at scale.

Talk to our partnerships team
Precision Pipeline
Live analysis
Liquid Biopsy
Biotech partner: cfDNA, methylation, ctDNA
+
AI Imaging
Oatmeal CADx: LDCT radiomics, morphology
=
Precision Score
Combined molecular + spatial risk stratification
34M+
accessible
Patient lives in network
>92%
combined
Specificity target
60%+
diverse
Minority enrollment
LungAI is an investigational medical device and has not been cleared by FDA. Oatmeal Health is preparing a 510(k) premarket notification for submission to FDA. LungAI is not commercially available in the United States. Clinical performance data reflect retrospective studies on held-out datasets; results may differ in prospective use.
The Opportunity

A blood test tells you cancer is there. Imaging tells you where it is.

Lung cancer screening today relies on low dose CT scans alone. By partnering with biotech companies that specialize in liquid biopsy, we add molecular signals from the blood that catch cancer biology early, while our AI powered imaging pinpoints exactly where. Together they reduce false positives, catch cancers earlier, and enable truly personalized risk stratification.

Liquid Biopsy (Biotech Partners)

Our biotech partners run blood based tests that detect cell free DNA fragments, methylation patterns, and tumor signals in the bloodstream. These molecular markers reveal whether cancer biology is present, often before symptoms appear.

AI Powered Imaging (Oatmeal Health)

Our CADx AI analyzes LDCT scans to assess nodule shape, density, texture, and growth patterns with radiomics. The spatial detail tells clinicians where the concern is, how large, and how it compares to known malignancy profiles.

Combined Precision Score

Fusing our biotech partners' molecular signals from blood with Oatmeal's spatial signals from imaging produces a single, higher confidence risk score. Research shows this combined approach can push specificity above 92% and significantly reduce unnecessary biopsies and follow up scans.

What We Bring

The infrastructure that takes years to build, ready now

Building community site relationships, earning credentialing, and deploying AI to find and reach patients typically takes sponsors years and millions of dollars. We have already done it.

Map of FQHC partner sites across the United States
1

Nationwide FQHC Partner Network

Established partnerships with Federally Qualified Health Centers across the country, serving 34M+ patients. Credentialed and ready for activation.

  • Rural, suburban, and urban sites across multiple states
  • Credentialed at partner sites, minimal setup
  • Expanding network with new sites added continuously
Medical imaging workstation with AI diagnostic screens
2

AI Powered Patient Identification

Our AI parses EHR data across structured and unstructured fields to find every patient who meets your protocol criteria, scored by risk, reachability, and eligibility confidence.

  • 0.96 AUROC risk and eligibility model
  • Epic, Athena, and other major EHR integrations
  • Customizable to your inclusion and exclusion criteria
Diverse group of senior adults in community health setting
3

Verified Diverse Patient Populations

Our patient base reflects the communities that clinical research has historically excluded. We have the demographic data and the community trust to enroll patients typically hardest to reach.

  • 60%+ racial and ethnic minority patients
  • Bilingual outreach in English and Spanish
  • Verified demographic reporting for FDA DAP
AI powered patient engagement platform
4

AI Powered Patient Engagement

Our AI agents reach eligible patients through text and conversational messaging, trained on your specific therapeutic area. They educate, answer questions, and schedule visits at scale in multiple languages.

  • AI agents trained on your protocol and therapeutic focus
  • Bilingual text based outreach at unlimited scale
  • Real time enrollment dashboard and reporting
Partner With Us

One network. Every use case your program needs.

Whether you are enrolling a pivotal trial, validating a liquid biopsy diagnostic, building real world evidence, or meeting FDA diversity requirements, Oatmeal Health connects you to the community patient populations that make the difference.

Phase I through IV

Clinical Trial Recruitment

Most trials underenroll patients from low income and minority communities, not because they do not qualify, but because no one has reached them. Our FQHC network changes that. AI eligibility screening against your protocol criteria, bilingual outreach, and credentialed sites ready from day one.

Precision Medicine

Liquid Biopsy + AI Imaging Validation

Biotech partners bring blood based tests, we bring the AI imaging and patient infrastructure. Together we validate combined detection models against real world, diverse patient cohorts at community health sites. We provide the patient volume, the imaging pipeline, and the longitudinal data needed to prove that molecular plus spatial approaches work outside of academic centers.

Real World Evidence

Post Approval and Outcomes Studies

Generate longitudinal EHR and screening outcomes data from the populations who actually use your therapy. Our network produces real world evidence from diverse communities with HIPAA compliant data sharing and BAA ready infrastructure.

FDA DAP

FDA Diversity Requirements

The FDA Diversity Action Plan requirements are not going away. More than 60% of our patients come from racial and ethnic minority communities, with verified demographic documentation for regulatory submissions. African American, Hispanic/Latino, Asian, and Native American patients.

Research team working in a clinical laboratory environment
How It Works

From protocol to enrolled patient in weeks, not years

We handle the infrastructure. You focus on the science.

1

We scope the program together

We start with a call to understand your protocol, enrollment targets, diversity requirements, and timeline. Our team maps your inclusion and exclusion criteria against our patient network to give you a realistic enrollment estimate before you commit to anything.

Protocol Review Feasibility Assessment Enrollment Estimate
2

We configure our AI and activate sites

Our AI is configured to your specific eligibility criteria and run against EHR data at our partner sites. We identify and rank every patient who qualifies, then activate outreach through the appropriate channels in the patient's preferred language.

AI Eligibility Screening Site Activation Bilingual Outreach
3

We enroll, track, and report in real time

Consented patients are scheduled for screening, baseline visits, or study procedures depending on your protocol. Our dashboard gives you real time enrollment numbers, demographic breakdowns, and site level performance. We handle reminders, rescheduling, and retention support throughout the study period.

Real Time Dashboard Demographic Reporting Retention Support
Get Started

Let's talk about your program

Tell us about your trial, study, or validation program and we will tell you exactly what enrollment from our network looks like. No commitment required to get a feasibility assessment.

Clinical Trials
Phase I through IV oncology enrollment
Precision Medicine
Liquid biopsy + imaging validation
Diagnostics
Real world validation at community sites

Prefer a direct conversation? Email hello@oatmealhealth.com
We respond within one business day.